MARKET

EYES

EYES

Second Sight Med
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9293
+0.1138
+13.95%
After Hours: 0.9347 +0.0054 +0.58% 17:12 04/08 EDT
OPEN
0.8537
PREV CLOSE
0.8156
HIGH
1.000
LOW
0.8151
VOLUME
368.49K
TURNOVER
--
52 WEEK HIGH
9.60
52 WEEK LOW
0.7100
MARKET CAP
14.55M
P/E (TTM)
-0.0497
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EYES stock price target is 7.25 with a high estimate of 12.00 and a low estimate of 2.500.

EPS

EYES News

More
  • The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation
  • Benzinga · 1d ago
  • Company News for Apr 1, 2020
  • Zacks · 04/01 14:04
  • The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests
  • Benzinga · 04/01 11:38
  • The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions
  • Benzinga · 03/31 12:26

Industry

Medical Equipment, Supplies & Distribution
+4.22%
Healthcare Equipment & Supplies
+4.03%

Hot Stocks

Symbol
Price
%Change

About EYES

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.
More

Webull offers kinds of Second Sight Medical Products Inc stock information, including NASDAQ:EYES real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYES stock news, and many more online research tools to help you make informed decisions.